CompletedPhase 2Phase 3ACTRN12611000651987

Platelet rich plasma injection for treatment of osteoarthritis

The effects of intra-articular injection of platelet rich plasma on pain and function in patients with knee osteoarthritis: A randomised controlled trial.


Sponsor

Kade Paterson

Enrollment

30 participants

Start Date

Jul 28, 2011

Study Type

Interventional

Conditions

Summary

Osteoarthritis (OA) is a progressive degenerative disease characterised by loss or damage of the cartilage surface of joints, resulting in pain and disability. Unitl recently, management of mild to moderate OA has been limited to symptomatic relief with analgesia or anti-inflammatory medications, viscosupplementation and exercise therapy, and in extreme cases joint replacement surgery. An emerging treatment for soft tissue healing and bone mineralisation is platelet rich plasma (PRP) injection. In addition to clotting functions, activated platelets have been found to contain growth factors, cytokines and protiens responsible for promotion of tissue regeneration and healing. Injection of PRP solution to joints during surgical procedures have demonstrated positive effects on healing, pain and function post-operatively. However, to our knowledge, there are limited ramdomised controlled studies evaluating the effect of a less invasive technique of intra-articular injection of PRP. Therefore, this double blinded study aims to assess the changes in pain, activity levels and lower extremity functional ability of patients with mild to moderate OA following intra-articular PRP injection compared to usual treatment of Hylan G-F 20 (SYNVISC).


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests platelet-rich plasma (PRP) injections as a treatment for osteoarthritis in adults aged 18-80. PRP is made from the patient's own blood and contains growth factors that may help reduce pain and promote joint healing.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

To make the platelet rich plasma (PRP), 20 ml of the patient’s blood will be collected and centrifuged at 100g for 5 minutes. The plasma and buffy coat will be drawn from the top, placed in a sterile

To make the platelet rich plasma (PRP), 20 ml of the patient’s blood will be collected and centrifuged at 100g for 5 minutes. The plasma and buffy coat will be drawn from the top, placed in a sterile tube and activated using low-level light irradiation. The activated PRP will then be injected into the patient's symptomatic knee under ultrasound guidance. Patients will receive three injections each of 5ml platelet-rich plasma one week apart. Time-points for injections: 1) initial injection, 2) one week following initial injection and 3) two weeks following initial injection. This results in a total treatment duration of two weeks.


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000651987


Related Trials